Translational Partnerships Calibr-Skaggs operates as a leading nonprofit drug discovery engine within Scripps Research, focused on moving discoveries into the clinic across multiple disease areas. The institute has recently secured financing to advance platform-targeted neurodevelopmental disorder work and engages in collaborations such as RNA screening initiatives. This signals openness to co-development, licensing, or sponsored research with pharma and biotech partners to validate targets, advance preclinical programs, and co-create diagnostics.

Data and Cloud With a tech stack that includes Google Cloud, Hadoop, SciPy, and other data tools, the institute demonstrates strong computational biology capabilities and a data-driven research model. This creates opportunities to offer cloud-enabled analytics, data integration, pipeline automation, and AI/ML support to accelerate target discovery, biomarker work, and translational studies.

Funding Partnerships Revenue is in the 50 to 100 million range for a nonprofit research organization, and the group has a track record of industry partnerships and academic collaborations. This ecosystem suggests receptivity to funded collaborations, sponsored research, licensing deals, or joint grant programs that align with translational timelines and milestone-based outcomes.

Clinical Translation The institute emphasizes end-to-end translation from discovery to clinic, including translational platforms and potential diagnostic development such as at-home RNA tests. This positions it to engage in CRO-type services, assay development, biomarker validation, regulatory strategy, and early-phase preclinical work that partners may outsource or co-fund.

Strategic Access Located in La Jolla as part of Scripps Research and with partnerships across academia and industry, Calibr-Skaggs can serve as a gateway to academic collaborations, joint ventures, and cross-institution programs. Business development opportunities include sponsored research networks, co-funded centers, and cross-cluster partnerships with pharmaceutical companies seeking access to translational platforms and expertise.